Yeasen Biotechnology Secures Nearly RMB 300 Million in Series B+ Financing to Accelerate Molecular Enzyme Innovation and Life Science Industrial Expansion

Recently, Yisheng Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as "Yeasen") announced the completion of its Series B+ financing round, raising nearly RMB 300 million.Led by CPE Yuanfeng, with follow-on investments from Huimei Capital, Haiwang Capital, Huasai Fund, and Honghou Kangrui, having previously secured investments from Legend Capital, Hantai Venture Capital, and Anhui Tanbing, among others. The proceeds from this round of financing will be primarily used to increase R&D investment in molecular enzymes and related tool products under Yeasen, as well as to expand multiple domestic R&D and industrialization bases for molecular enzymes.

Regarding the consecutive investment recognitions from capital investors,Huang Weihua, Founder and Chairman of Yeasenstated: “We appreciate the recognition and expectations from CPE Yuanfeng, Huimei Capital, Haiwang Capital, Huasai Fund, Honghou Kangrui, and existing shareholder Shanghai Haoxing toward Yeasen. Yeasen will integrate into ‘+Internet” strategy, integrating data platforms with actual business operations to drive business upgrades and enhance management efficiency, while continuously providing customers with high-quality molecular enzyme products and improving raw material accessibility. We are committed to helping customers create value and tirelessly working towards our mission of making the world healthier and happier.”

Yeasen, founded in 2014, is a company focused onEnzyme Raw Materials for ToolsandAntigen-AntibodyA high-tech enterprise engaged in R&D and production, committed to providing high-quality products and premium services to customers in the life sciences sector. Since its establishment, the company has focused on the research, development, and manufacturing of molecular enzyme raw materials, striving to overcome critical technical bottlenecks in molecular enzymes previously dominated by imports. It is dedicated to achieving domestic import substitution and reshaping the competitive landscape of the market.

This financing will further support Yeasen’s rapid and steady development, accelerate the R&D and upgrading of its core molecular enzyme technologies, and speed up the development of molecular enzymes as well as tool-type reagents and kits.Localization, continuously empowering China's "intelligent manufacturing."

In the field of molecular enzymes, Yeasen has established a completeInnovation, TranslationandProductionIts portfolio of molecular enzyme products covers basic biological reagents for scientific research, including PCR, qPCR, RT-PCR, cloning, cell culture and assay, mycoplasma prevention and detection, and antigens and antibodies, as well as core enzyme formulations for precision medicine, high-throughput sequencing kits, molecular diagnostic testing kits, and reagents and kits for drug production materials and testing. The related molecular diagnostic enzyme raw materials and pharmaceutical-grade enzyme raw materials meet international top-tier quality standards.

Furthermore, Yeasen continues to advance its enzyme evolution and engineering initiatives. The company has established the Yeasen Biotechnology Research Institute in Shanghai, inviting top professors and experts from across China in the fields of protein engineering and evolution. This effort aims to promote application-oriented enzyme optimization and translate cutting-edge molecular enzymology research into practical applications within the life sciences sector.

To meet the needs of customers in various fields such as scientific research, in vitro diagnostics, and biotherapy, Yeasen has establishedYeasen R&D Center, including the In Vitro Diagnostics Research and Development Center (IVD RDC), the Next-Generation Sequencing Research and Development Center (NGS RDC), and the Molecular Enzyme Research and Development Center.

Specifically, the IVD RDC and NGS RDC leverage diversified product portfolios and extensive application case studies to facilitate the rapid development of tailored molecular enzyme products for customers; meanwhile, the Molecular Enzyme R&D Center establishes a comprehensive molecular enzyme library and optimizes scale-up processes, ensuring stable mass production of customer-required products. Leveraging these platforms, Yeasen has achieved technological breakthroughs in enzyme research and development, functional protein products, and other areas, enabling it toDevelopment of Specialty Enzymes, and achieveTon-Scale Protein Fermentation。

To provide customers with highly stable and high-quality products, Yeasen has also established in WuhanUltra-Clean Molecular Enzyme Industrialization Center（UCF.ME^®, Ultra Clean Factory for Molecular Enzyme), covering an area of 3,000 square meters, equipped with hectoliter-scale fermentation lines, industrial-grade AKTA purification lines, and fully automated packaging lines. It strictly adheres to ISO 13485 and GMP standards and has obtained ISO 13485:2016 certification for medical device quality management systems.

In the current era of normalized epidemic prevention and control, the significant role of technology has become increasingly evident. In June 2021,Yeasen Baiying Data CenterOfficially launched, Yeasen aims to build an efficient and innovative operational system. By leveraging big data to better serve its customers, Yeasen will support the informatization and intelligent development of the life sciences sector, thereby driving innovative growth in the biotechnology industry.

Regarding the investment in Yeasen,Chen Jinhao, Managing Director of CPE Yuanfeng“The Yeasen team has been deeply engaged in the life sciences sector for many years, accumulating extensive industry insights. Leveraging its strong R&D capabilities and stable industrial-scale manufacturing capacity, Yeasen has established a solid reputation among customers across biopharmaceuticals, diagnostics, scientific research, and other life science fields. The company has built a robust portfolio of technological products and is progressively evolving into a platform-oriented enterprise serving customers throughout the entire life sciences ecosystem. CPE Yuanfeng maintains a long-term positive outlook on the life sciences sector and has already established strategic investments along the industry chain. Moving forward, CPE Yuanfeng will further support Yeasen in expanding its product lineup and customer reach, helping to position the company as a leading enterprise in the life sciences industry.”

Luo Rushu, Founding Partner of Huimei Capital“He stated: ‘Molecular enzymes are not only vital tools in life sciences but also hold great promise for numerous downstream applications, offering a broad market outlook. Currently, the high reliance on imported molecular enzyme products has become a critical bottleneck affecting the supply of research and diagnostic products. Yeasen prioritizes R&D and production, continuously refining its product portfolio to offer a diverse range of high-quality products capable of stable mass production. We look forward to Mr. Huang leading Yeasen in further expanding its footprint, solidifying its competitive advantages in life science tools and in vitro diagnostic raw materials, exploring new application scenarios, and making greater contributions toward achieving self-sufficiency and control over key biological raw materials in China.’”

Wang Ying, Head of Biopharmaceutical Investment at Pudong Sci-Tech Innovation (Haiwang Capital)“It has always been Pudong Sci-Tech Innovation’s commitment to focus on hard technology, investing in the upstream of the industrial chain, the top end of the value chain, and the foundational layers of technological systems. As a leading enterprise in the upstream segment of the life sciences industry chain, Yeasen represents a key component of our recent investment layout in biomedicine. We will continue to support more high-quality projects similar to Yeasen in this field, aiming to address bottleneck technologies and weak links within the biomedical industry.”

CPE Yuanfeng is an asset management firm with a global perspective and extensive experience in China. Dedicated to a long-term horizon and value investment strategies, CPE focuses on providing innovative investment solutions to leading enterprises in four key sectors: Healthcare & Wellness, Consumer & Internet, Technology & Industry, and Software & Enterprise Services. Currently, funds under CPE’s management have earned the trust and support of more than 200 institutional investors both domestically and internationally, with cumulative assets under management exceeding RMB 100 billion. Over the past decade, the company’s core team has invested in more than 200 enterprises, accumulating profound industry insights and an extensive resource network. Leveraging a robust investment research framework and professional post-investment management capabilities, CPE is committed to building long-term partnerships with its portfolio companies. It aims to facilitate their sustainable development, deliver substantial returns to investors, drive the overall advancement of the industries in which these companies operate, and create positive social impact.

Huimei Capital is a professional investment fund dedicated to healthcare and medical sectors. Leveraging the ecosystem advantages of Huimei Medical Group, it invests in the healthcare ecosystem through multi-dimensional and comprehensive approaches, striving to build a professional investment platform with global vision and local execution capabilities, thereby helping early-stage and growth-stage healthcare enterprises achieve rapid development. Huimei Capital works closely with innovative, fast-growing healthcare companies, providing comprehensive strategic value-added services and systematic empowerment from a global perspective, and sharing its global business network and resource system with outstanding entrepreneurs.

Pudong Sci-Tech Innovation (Haiwang Capital) is a fund operation platform established by Pudong Sci-Tech Innovation Group, focusing on the New Area’s “Six Core Hard-Tech” industries. It manages funds such as the Shanghai Aviation Industry Fund, Haiwang Integrated Circuit Fund, Haiwang Culture and Technology Fund, Haiwang Intellectual Property Fund, and the SME Development Fund, with assets under management exceeding RMB 10 billion. The platform supports Pudong’s high-quality development and contributes to building a pioneering zone for socialist modernization.

Huasai Zhikang (Shanghai) Equity Investment Fund Partnership (Limited Partnership) (“Huasai Fund”) is a subsidiary fund managed by Shanghai Sailings Capital Management Co., Ltd. (“Shanghai Sailings”), focusing on investment opportunities in the fields of biopharmaceuticals, advanced manufacturing, and integrated circuits. Shanghai Sailings serves as the domestic governing body of the RMB International Loan and Investment Fund—Sailings International Investment Fund (“Sailings Fund”), which was jointly established under the leadership of the People’s Bank of China, the Shanghai Municipal Government, and relevant national authorities. It specializes in promoting RMB internationalization and investing in, as well as facilitating mergers, acquisitions, and integration for, dominant industries and enterprises both domestically and internationally. Leveraging Shanghai Sailings’ high-quality resources in capital markets, regulatory bodies, and the Shanghai state-owned assets system, along with its local state-owned background, Huasai Fund helps empower portfolio companies in their initial public offerings (IPOs), enhances their recognition in capital markets, and provides comprehensive support for the long-term, stable development of its projects.

Yeasen Biotechnology (Shanghai) Co., Ltd. was established in 2014 and has long been dedicated to the research, development, and production of molecular enzyme raw materials and library preparation kits. Our goal is to help downstream enterprises reduce costs and contribute to the advancement of precision medicine in China. Yeasen possesses advanced technological platforms, including a bidirectional molecular enzyme technology platform, large-scale protein fermentation and purification platform, and high-efficiency antibody screening platform. To date, we have successfully developed and achieved industrial-scale production of more than 40 types of products, such as diagnostic molecular enzymes and next-generation sequencing (NGS) library preparation enzymes. The enzyme raw materials developed by Yeasen for genetic testing and in vitro diagnostics (IVD) have gained widespread recognition from customers. Furthermore, we provide customized development services for industrial clients to meet their personalized needs.